• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Clopidogrel High-on-Treatment Platelet Reactivity in Acute Ischemic Stroke Patients
Conclusions: Clopidogrel-HTPR was found in 44% of the patients with acute ischemic stroke. Besides time-dependency of the clopidogrel effect, major risk factors for clopidogrel-HTPR were diabetes mellitus and higher HbA1c values. Further investigations are required to analyse if a function test guided strategy has the potential to optimize the antiplatelet therapy of acute stroke patients.
Source: Thrombosis Research - January 9, 2014 Category: Hematology Authors: Saskia H. Meves, Kay D. Schröder, Heinz G. Endres, Christos Krogias, Jan C. Krüger, Horst Neubauer Tags: Platelets and cell biology Source Type: research

VASP phosphorylation and genetic polymorphism for clopidogrel resistance in Chinese patients with non-cardioembolic ischemic stroke
Clopidogrel resistance(CR)is found in non-cardioembolic ischemic stroke (NCIS) patients. However, it is still largely unknown how to identify CR in NCIS patients by laboratory and genetic characteristics.
Source: Thrombosis Research - October 10, 2014 Category: Hematology Authors: Shijun Zhang, Xinqiang Lai, Wenxian Li, Zhen Jing, Zhilin Xiong, Anding Xu, Yiwen Ruan, Li'an Huang Tags: Regular Article Source Type: research

An optimum prophylactic dose of prasugrel monotherapy may safely and effectively prevent the development of experimental thrombotic strokes
Myocardial infarction and stroke are two of the leading causes of death and disability worldwide [1,2]. Using a combination of aspirin and a platelet P2Y12 antagonist, several large clinical trials have definitively demonstrated the efficacy of dual antiplatelet therapies in preventing myocardial infarction, stroke or death in patients with acute coronary syndromes [3–8]. Dual antiplatelet therapy with aspirin and a thienopyridine-based P2Y12 antagonist (clopidogrel or prasugrel) has now become the standard of care of patients with acute coronary syndromes.
Source: Thrombosis Research - October 16, 2015 Category: Hematology Authors: Frederick A. Ofosu Source Type: research

Platelet reactivity in patients carrying the e-NOS G894T polymorphism after a loading dose of aspirin plus clopidogrel
Nitric oxide (NO) plays an important role in the modulation of platelet reactivity through platelet recruitment, activation and aggregation. NO is produced by the endothelial NO synthase (eNOS) that is expressed not only in the endothelium but also in platelets [1]. G894T single nucleotide polymorphism of eNOS gene results in the substitution of glutamic acid at codon 298 by aspartic acid. This substitution in the protein sequence is responsible of lower enzyme activity, i.e. lower NO production, and it has been associated with coronary spasm, atherosclerosis, myocardial infarction, and stroke [2 –6].
Source: Thrombosis Research - January 25, 2017 Category: Hematology Authors: Teresa Strisciuglio, Giuseppe Di Gioia, Fabio Mangiacapra, Chiara De Biase, Leen Delrue, Mariano Pellicano, Jozef Bartunek, Marc Vanderheyden, Raffaele Izzo, Bruno Trimarco, William Wijns, Emanuele Barbato Tags: Letter to the Editors-in-Chief Source Type: research